Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected Pancreatic Cancer.

CONCLUSION: Post-treatment SII may be a useful prognostic marker in PDAC patients receiving NAT.
PMID: 31792715 [PubMed - as supplied by publisher]

Source: Ann Oncol - December 1, 2019 Category: Cancer & Oncology Authors: Murthy P, Zenati MS, Al Abbas AI, Rieser CJ, Bahary N, Lotze MT, Zeh HJ, Zureikat AH, Boone BA Tags: Ann Surg Oncol Source Type: research